Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Pain 5Neoplasms 5Cancer Pain 2Neuralgia 1Chronic Pain 1Breast Neoplasms 1Agnosia 1

Interventions

Fentanyl 27Analgesia 23Morphine 20Acupuncture Therapy 18Surveys and Questionnaires 16Oxycodone 16Zoledronic Acid 15Acetaminophen 14Therapeutics 13Radiotherapy 13Psychiatric Rehabilitation 13Ketamine 13Methadone 11Lidocaine 11Hydromorphone 11Bupivacaine 11nabiximols 10Ibandronic Acid 10Ropivacaine 9Early Intervention, Educational 7Analgesics, Opioid 7Saline Solution 6Music Therapy 6Cryotherapy 6Cryosurgery 6Yoga 5Water 5Tapentadol 5Pregabalin 5Methods 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Pain × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01264887 2019-11-04

Tapentadol in Chronic Malignant Tumour Related Pain

Grünenthal GmbH

Phase 3 Terminated
31 enrolled 19 charts

Agnosia, Neoplasms, Pain, Chronic Pain

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

NCT01165281 2017-07-21

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Janssen Research & Development, LLC

Phase 3 Completed
343 enrolled 15 charts

Pain

NCT00805142 2013-07-29

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Janssen Pharmaceutical K.K.

Phase 2 Completed
78 enrolled 16 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡